In vitro activity of the new glycopeptide decaplanin

The activity of decaplanin, a new glycopeptide, was compared to that of vancomycin, teicoplanin and daptomycin. Decaplanin was two- to four-fold less active than vancomycin, teicoplanin and daptomycin againstStaphylococcus aureus andStaphylococcus epidermidis, with an MIC90 of 2 µg/ml for methicillin-susceptible and 4 µg/ml for methicillin-resistant isolates. Decaplanin had activity similar to that of vancomycin againstStreptococcus pyogenes, Streptococcus agalactiae, group C and G streptococci, with an MIC90 of 0.12 µg/ml. It was less active than the other agents against the viridans group streptococci (MIC90 4 µg/ml). The activity of decaplanin against enterococci (MIC90 4 µg/ml) was similar to that of vancomycin.Clostridium spp. were inhibited by 0.5 µg/ml, peptostreptococci and peptococci by 0.25 µg/ml. Decaplanin was active from pH 5.5 to 7.5. Inoculum size had a minimal effect on MICs, and increased concentrations of Ca²⁺ and Mg²⁺ and 50 % serum did not alter MICs or MBCs.